Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 16 tags : Phase 3 save search
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet Neurology
Published: 2021-06-16 (Crawled : 23:00) - globenewswire.com
ARGX | $376.41 -0.43% -0.43% 190K
|
Health Technology
|
| O: -0.75%
H: 2.48%
C: 1.48%
treatment results phase 3 trial trial results lancet
Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
TARS | $35.02 -3.18% -3.28% 330K
|
Health Technology
|
| O: 0.23%
H: 1.5%
C: 0.71%
disease phase 1 vaccine trial phase 3 phase 2
Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety Results From Phase 1 Trial of STS101 at Multiple Dose Strengths
Published: 2021-06-16 (Crawled : 22:00) - biospace.com/
STSA | $1.1 -0.9% -0.91% 0
|
Health Technology
|
| O: -0.41%
H: 1.43%
C: 1.02%
phase 1 positive results trial phase 3 phase 2
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
Published: 2021-06-16 (Crawled : 13:00) - biospace.com/
APRE | $5.75 0.7% 0.7% 8.4K
|
Health Technology
|
| O: 50.72%
H: 6.7%
C: -26.4%
phase 1 trial phase 3 phase 2 aml
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
FRLN | $6.48 0.0% 0
|
Health Technology
|
| O: 4.52%
H: 0.0%
C: -4.93%
disease phase 1 trial phase 3 phase 2
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers
Published: 2021-06-16 (Crawled : 12:00) - biospace.com/
ALT | $7.56 -5.38% -5.69% 3.5M
|
Commercial Services
|
| O: 2.19%
H: 34.76%
C: 13.99%
phase 1 positive trial phase 3 phase 2 obesity
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Published: 2021-06-16 (Crawled : 11:00) - globenewswire.com
SWTX | $42.55 -0.47% -0.47% 560K
|
Health Technology
|
| O: 0.08%
H: 1.02%
C: -0.11%
phase 1 children trial phase 3 phase 2
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Published: 2021-06-16 (Crawled : 06:00) - prnewswire.com
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.15%
H: 0.3%
C: -0.78%
REGN | $898.33 -0.7% -0.71% 650K
|
Health Technology
|
| O: 0.7%
H: 2.12%
C: -1.43%
covid casirivimab phase 3 trial sars-cov-2
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.